Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Mobilized peripheral blood input
What ifWhat if the starting cells come from mobilized adult peripheral blood?
Claim language“umbilical cord blood or placental blood cells”
Leukapheresis collects circulating nucleated cells after cytokine-mediated mobilization. Anti-CD34 immunomagnetic selection recovers hematopoietic stem and progenitor cells for expansion and myeloid differentiation.
1.2Direct monocyte isolation
What ifWhat if the preparation starts with purified mature monocytes?
Claim language“enriched CD34+ hematopoietic stem and progenitor cells”
Immunomagnetic selection captures CD14+ monocytes from a blood mononuclear cell fraction. The purified monocytes enter macrophage differentiation culture directly with monocyte colony stimulating factor.
What ifWhat if interleukin-34 provides the macrophage differentiation signal?
Claim language“granulocyte-macrophage colony stimulating factor or M-CSF”
Recombinant interleukin-34 binds the colony stimulating factor 1 receptor on monocytes and supports their survival and differentiation into macrophages. Flow cytometry measures HLA-DR, CD11b, CD14 and CD16 at harvest to characterize the resulting population.
1.6Cytokine activation of macrophages
What ifWhat if soluble cytokines trigger macrophage activation during a functional assay?
Claim language“activated by pathogens or tumor cells”
Recombinant interferon gamma activates signaling through its receptor on differentiated macrophages. Flow cytometry compares surface HLA-DR on cytokine-treated cells and untreated cells from the same preparation.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Macrophage assay for implant materials
The three-stage culture supplies macrophages for an in vitro assay of implant materials. Flat material coupons sit in multiwell plates, and each well receives the same number of viable macrophages from one preparation. Parallel wells contain macrophages on a reference surface and coupons without cells. Microscopy measures cell attachment and spreading, and an immunoassay measures interleukin-6 in the spent medium.
Component substitution
Synthetic hydrogel support for monocyte culture
A crosslinked polyethylene glycol hydrogel bearing covalently attached arginine-glycine-aspartate peptides replaces the solid support in the monocyte differentiation phase. The hydrogel forms a thin layer on the base of each culture well and is equilibrated with differentiation medium before cell transfer. The peptide groups provide integrin binding sites at the medium-facing surface. At harvest, the suspension fraction and the cells released from the surface are combined for counting and flow cytometry.
Parameter or scale variation
Parallel scale increase in culture flasks
Four 175 cm² flasks replace one 175 cm² flask in each solid-phase stage, increasing the total culture area to 700 cm². Each flask receives 35 mL of medium, giving a nominal liquid depth of 2 mm. The inoculum is divided equally by viable cell count, and each flask receives its medium exchanges separately. Cells from the four flasks are pooled and counted at each stage transfer.
Combination with existing systems
Closed harvest with centrifugal cell washing
The macrophage differentiation vessel connects to a closed centrifugal cell washer through sterile tubing. The harvest enters a disposable chamber, where centrifugation retains the cells while spent medium drains to a waste bag. The washer resuspends the retained cells in an isotonic wash solution and repeats the separation. The final suspension transfers into a collection bag with a sampling port for viable cell counts and marker measurements.
Macrophage culture in a perfused tissue chip
Macrophages from the final differentiation stage enter the tissue compartment of a perfused microfluidic chip containing a stromal cell matrix. A porous membrane separates the tissue compartment from a medium channel connected to a syringe pump and an outlet reservoir. The pump supplies medium through the channel, and solutes exchange across the membrane. Time-lapse microscopy tracks macrophage movement through the matrix, and outlet samples provide measurements of secreted cytokines.
Automated or data-driven variant
Automated monitoring of culture stage transfers
An automated sampler delivers aliquots from each culture vessel to a cell counter and a flow cytometer. Software calculates viable cell concentration and the fraction of live singlets that express both CD11b and HLA-DR. The software compares those measurements with configured criteria for the current culture stage and sends a transfer signal to the liquid handler when the criteria are met. The system records the measurements, stage identifier, and transfer time for each vessel.
Specific version of a part
Closed cord blood collection
A sterile collection bag containing citrate anticoagulant receives blood through a needle inserted into the umbilical vein. Gentle mixing distributes the anticoagulant throughout the collected blood.
Magnetic CD34 cell enrichment
Density-gradient centrifugation separates mononuclear cells from most red blood cells. Anti-CD34 magnetic particles bind progenitors, and a magnetic column retains the labeled cells while unlabeled T cells pass through.
Macrophage differentiation with human serum
Macrophage differentiation medium contains recombinant monocyte colony stimulating factor and pooled human serum. The cytokine supports monocyte survival and maturation, while the serum supplies albumin, lipids and other soluble proteins.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1selecting a plurality of umbilical cord blood or placental blood cells;
Mononuclear cell is obtained by collecting bone marrow, cord blood or peripheral blood from an animal, subjecting same to, for example, density gradient centrifugation method and extracting the fraction.
B · US 2015/0238538 A1 · ¶ 39
1.2preparing enriched CD34+ hematopoietic stem and progenitor cells (HSPCs) that are depleted of red blood cells and T cells;
In addition, the present inventors have shown a method of efficiently proliferating CD34 and/or CD133 positive cells from bone marrow mononuclear cells (patent document 3).
B · US 2015/0238538 A1 · ¶ 2
1.3culturing the CD34+ enriched HSPCs in an expansion culture medium comprising interleukin-3 (IL-3), interleukin-6 (IL-6), thrombopoietin (TPO), Flt-3 ligand (Flt-3L), and stem cell factor (SCF) on a solid phase for a sufficient time to produce expanded HSPCs, wherein the expanded HSPCs do not substantially differentiate into CD11b+ HLA-DR+ cells during the expansion; and
IL-6 potentiates the proliferative effect of IL-3 on multipotential hematopoietic progenitors.
A · US 2014/0255337 A1 · ¶ 87
As a result, they have succeeded in efficient proliferation of a cell population containing EPC in vitro by cultivating mononuclear cells in a serum-free culture medium containing a factor selected from the group consisting of (1) a stem cell factor (SCF), (2) interleukin-6 (IL-6), (3) FMS-like tyrosine kinase 3 ligand (FL) and (4) thrombopoietin (TPO) and (5) a vascular endothelial growth factor (VEGF).
B · US 2015/0238538 A1 · ¶ 10
1.4culturing the expanded HSPCs in an expansion and monocyte differentiation culture medium comprising effective amounts of Flt-3 ligand (Flt-3L), interleukin 3 (IL-3), and monocyte colony stimulating factor (M-CSF) and/or granulocyte-macrophage colony stimulating factor (GM-CSF) on a solid phase for a sufficient time to produce expanded HSPCs and monocytes, the cell composition comprising an average of about 40 to about 80% HLA-DR+ CD11b+ cells and an average of about 20 to about 60% other myeloid cells, the cell population also comprising about 70% CD14+ CD16+ cells;
1.5culturing the expanded HSPCs and monocytes in a macrophage differentiation culture medium comprising effective amounts of granulocyte-macrophage colony stimulating factor or M-CSF and serum or a non-animal sourced serum replacement for a sufficient time to produce a macrophage cell composition and/or preparation comprising about 60 to about 90% HLA-DR+ CD11b+ cells and an average of about 10 to about 40% other myeloid cells, the cell population also comprising about 7% CD14+ CD16− cells, about 66% CD14+ CD16+ cells, and about 5% CD14− CD16+ cells; and
Monocytes exit the circulation and migrate into tissue, whereupon they mature into macrophages.
A · US 2014/0255337 A1 · ¶ 97
[6] A method of producing a cell population wherein a vascular endothelial progenitor cell and/or an anti-inflammatory macrophage are/is enriched, comprising cultivating a mononuclear cell derived from bone marrow, cord blood or peripheral blood in a serum-free medium containing stem cell factor, interleukin-6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor.
B · US 2015/0238538 A1 · ¶
1.6wherein the macrophages can be activated by pathogens or tumor cells.
It is thus part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection.
A · US 2014/0255337 A1 · ¶ 97
An empty cell means only that no passage was reproduced there.
Statements in these documents
Accordingly, the problem of the present invention is to simplify a preparation step of a cell population used for the treatment of ischemic diseases, and provide a cell population that shows more effect by the treatment.
B · US 2015/0238538 A1 · ¶ 9
Furthermore, the present inventors have clarified that a cell population having a similar function can also be obtained in cell populations collected from not only healthy individuals but also diabetes patients.
B · US 2015/0238538 A1 · ¶ 10
Cite aspatent.fyi, US 2026/0355236 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355236/, SHA-256 4cd2500efc16f70d087afa47ded30216bd010a379b0c97d8817e853344987bc4